SOR2 Antibody

What is SorCS2 and why is it significant in neuroscience research?

SorCS2 is a type I transmembrane glycoprotein receptor belonging to the mammalian Vps10p (vacuolar protein-sorting 10 protein) family. It plays a critical role in receptor trafficking, particularly in neuronal cells. SorCS2 is predominantly expressed in the brain, especially during development, but is also found in kidney, lung, testis, and heart tissues . Its significance in neuroscience stems from its involvement in glutamate receptor trafficking, particularly the N-methyl-D-aspartate receptor 2A (NR2A) subunit, which is crucial for synaptic plasticity and neurotransmission. Research has implicated SorCS2 dysfunction in several neurological disorders, including Huntington's disease, making it an important target for studies on neuronal function and pathology.

What are the structural characteristics of SorCS2 that researchers should consider when selecting antibodies?

Human SorCS2 is synthesized as a 1159 amino acid (aa) prepro form with a 50 aa signal sequence and a potential furin-type proteolytic processing site at aa 119. The mature SorCS2 protein consists of 1040 aa with a 959 aa extracellular/lumenal domain (ECD), a 21 aa transmembrane domain, and a 60 aa cytoplasmic domain . The ECD contains an imperfect leucine-rich repeat (LRR) and a Vps10p domain. When selecting antibodies, researchers should consider:

• Epitope location - antibodies targeting the ECD (particularly within the Ser70-Gly1078 region) have been successfully used in multiple applications

• Species cross-reactivity - human SorCS2 shares 89%, 88%, 88%, and 79% aa identity with mouse, rat, equine, and canine SorCS2, respectively

• Potential for cross-reactivity with other SorCS family members - SorCS2 shares 46% aa identity with the ECD of both SorCS1 and SorCS3

These structural considerations are essential for antibody selection to ensure specificity and appropriate binding to the target region.

How can researchers confirm the specificity of SorCS2 antibodies?

Confirming antibody specificity is crucial for obtaining reliable research results. For SorCS2 antibodies, researchers should implement the following validation approaches:

• Western blot analysis using tissue known to express SorCS2 (e.g., brain or kidney medulla) alongside negative controls

• Cross-validation with SorCS2-deficient tissue (from knockout models) to confirm absence of signals

• Competitive binding assays with recombinant SorCS2 protein

• Testing for cross-reactivity with related proteins (SorCS1, SorCS3) in overexpression systems

• Immunoprecipitation followed by mass spectrometry to confirm target identity

In published research, SorCS2 antibodies have been validated by Western blot showing specific bands at approximately 120 kDa in human kidney (medulla) tissue, with the absence of this band in SorCS2-deficient tissue serving as a negative control .

What are the optimal conditions for using SorCS2 antibodies in Western blot applications?

For successful Western blot detection of SorCS2, researchers should consider the following optimized protocol:

• Sample preparation: Use RIPA or similar buffer with protease inhibitors for tissue/cell lysis

• Gel conditions: 8-10% SDS-PAGE gels are recommended due to SorCS2's high molecular weight (~120 kDa)

• Transfer parameters: Wet transfer at low voltage (30V) overnight at 4°C improves transfer efficiency of large proteins

• Blocking conditions: 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Primary antibody incubation: Use 1 μg/mL of anti-SorCS2 antibody (e.g., R&D Systems AF4238) in blocking buffer overnight at 4°C

• Secondary antibody: HRP-conjugated anti-sheep IgG (e.g., R&D Systems HAF016)

• Detection system: Enhanced chemiluminescence (ECL)

Critical considerations include running the gel under reducing conditions and using appropriate immunoblot buffer systems (e.g., Buffer Group 8 has been reported successful) . The expected molecular weight for SorCS2 is approximately 120 kDa.

What methodological approaches are recommended for SorCS2 immunohistochemistry in brain tissue?

Optimal immunohistochemistry for SorCS2 in brain tissue requires attention to several critical steps:

• Tissue preparation: Immersion-fixed, paraffin-embedded sections have shown good results for human brain tissue

• Antigen retrieval: Heat-induced epitope retrieval using basic pH buffer (e.g., R&D Systems CTS013) is critical for unmasking SorCS2 epitopes

• Primary antibody concentration: 3-5 μg/mL applied overnight at 4°C has been reported as effective

• Detection system: HRP-DAB systems provide good visualization of SorCS2 in neuronal tissues

• Counterstaining: Hematoxylin provides contrast to visualize tissue architecture

SorCS2 exhibits specific staining localized to neurons and their processes in human brain tissue . When interpreting results, researchers should note that SorCS2 expression patterns may differ based on brain region, with strong expression observed in medium spiny neurons of the striatum in both human and mouse samples .

How can researchers effectively use co-immunoprecipitation to study SorCS2 interactions with other proteins?

Co-immunoprecipitation (co-IP) is a valuable technique for studying SorCS2 interactions with binding partners such as NR2A. Based on published research, an effective protocol includes:

• Tissue preparation: Homogenize fresh striatal tissue in non-denaturing lysis buffer containing 1% NP-40 or similar mild detergent with protease inhibitors

• Pre-clearing: Incubate lysate with protein A/G beads for 1 hour at 4°C to reduce non-specific binding

• Immunoprecipitation: Add 2-5 μg of SorCS2-specific antibody to 500-1000 μg of protein lysate and incubate overnight at 4°C

• Bead capture: Add protein A/G beads and incubate for 2-4 hours at 4°C

• Washing: Perform at least 4-5 washes with cold lysis buffer

• Elution and analysis: Elute in SDS sample buffer and analyze by Western blot

This approach has successfully demonstrated the interaction between SorCS2 and NR2A in striatal tissue, with appropriate controls including SorCS2-deficient tissue to confirm specificity . Reciprocal co-IP (using anti-NR2A antibody to pull down SorCS2) can provide additional validation of the interaction.

How can researchers differentiate between surface and intracellular SorCS2 expression in neurons?

Distinguishing between surface and intracellular pools of SorCS2 is crucial for understanding its trafficking and function. Researchers can employ several complementary approaches:

• Immunofluorescence with and without permeabilization:

  • Non-permeabilized: Detects only surface SorCS2

  • Permeabilized: Detects total SorCS2 (surface + intracellular)

• Surface biotinylation assay:

  • Biotinylate surface proteins using membrane-impermeable biotin

  • Isolate biotinylated proteins with streptavidin

  • Analyze SorCS2 levels by Western blot

• Quantitative immuno-electron microscopy:

  • Use gold-labeled secondary antibodies to detect SorCS2

  • Quantify distribution of gold particles on plasma membrane versus cytoplasm

  • This approach has been successfully applied to analyze NR2A trafficking in SorCS2-deficient mice

• Flow cytometry with differential staining:

  • Live cells: Surface staining only

  • Fixed/permeabilized cells: Total protein staining

By combining these approaches, researchers can generate quantitative data on the subcellular distribution of SorCS2 and monitor changes in response to experimental manipulations.

What considerations are important when interpreting temporal changes in SorCS2 antibody signals in longitudinal studies?

When conducting longitudinal studies involving SorCS2 detection, researchers should consider several factors that influence antibody signal stability and interpretation:

• Epitope stability over time:

  • Post-translational modifications may alter antibody recognition

  • Proteolytic processing may change epitope availability

• Protocol consistency:

  • Standardize fixation times, antibody concentrations, and incubation conditions

  • Include internal controls in each experimental batch

• Quantification methods:

  • Use ratio measurements relative to stable reference proteins

  • Consider digital image analysis with defined thresholds

• Statistical analysis:

  • Apply mixed-effect models to account for inter-individual variability

  • Consider non-linear regression for dynamic changes

Studies of other antibody responses have shown that time to signal loss (seroreversion) can vary dramatically between assays, ranging from 96 to 925 days depending on the assay platform . While these data are from SARS-CoV-2 studies, similar principles apply to SorCS2 detection, emphasizing the importance of assay selection and standardization in longitudinal research.

What methodological approaches can address the challenges of studying SorCS2 in disease models with protein mislocalization?

Studies of SorCS2 in disease states such as Huntington's disease (HD) present unique challenges due to altered subcellular localization patterns. Researchers can implement the following approaches:

• Subcellular fractionation:

  • Separate membrane, cytosolic, and nuclear fractions

  • Quantify SorCS2 distribution across fractions in disease versus control samples

• Multi-label confocal microscopy:

  • Co-stain with organelle markers (endoplasmic reticulum, Golgi, endosomes)

  • Quantify colocalization coefficients (Pearson's or Mander's)

• Proximity ligation assay (PLA):

  • Detect interactions between SorCS2 and binding partners with subcellular resolution

  • Compare interaction patterns in health and disease states

• Live-cell imaging with fluorescently tagged SorCS2:

  • Monitor trafficking dynamics in real-time

  • Quantify retention times in different cellular compartments

These approaches have revealed that in HD models and human HD tissue, SorCS2 exhibits altered distribution with reduced diffuse cytoplasmic localization and increased perinuclear clustering . Such methodological diversity allows researchers to characterize mislocalization patterns with precision and identify potential therapeutic targets.

How should researchers interpret differences in SorCS2 labeling patterns between brain regions and across species?

The interpretation of SorCS2 immunolabeling across different brain regions and species requires careful consideration of several variables:

• Expression level variations:

  • Striatum shows robust SorCS2 expression in multiple species

  • Cortical regions may show layer-specific patterns

  • Hippocampus and cerebellum have distinct expression profiles

• Cell-type specificity:

  • Medium spiny neurons show strong SorCS2 expression

  • Interneuron expression patterns may differ

  • Glial expression should be assessed separately

• Cross-species comparison challenges:

  • Antibody epitope conservation should be verified

  • Developmental timing differences may affect expression patterns

  • Fixation artifacts may vary between human and rodent tissues

• Quantification approaches:

  • Cell counting with defined positivity thresholds

  • Intensity measurements with background subtraction

  • Region-of-interest analysis to account for anatomical differences

When comparing human and mouse SorCS2 expression, researchers have noted similar patterns in the striatum, with expression in medium-sized neurons, but some species-specific differences in subcellular distribution . These differences must be considered when translating findings between animal models and human disease.

What statistical approaches are most appropriate for analyzing quantitative changes in SorCS2 expression across experimental conditions?

Appropriate statistical analysis of SorCS2 expression data depends on the experimental design and data characteristics:

• For comparing two experimental groups:

  • Student's t-test for normally distributed data

  • Mann-Whitney U test for non-parametric data

  • Consider paired tests for before-after comparisons in the same samples

• For multiple experimental groups:

  • One-way ANOVA with appropriate post-hoc tests (Tukey, Bonferroni) for normally distributed data

  • Kruskal-Wallis with Dunn's post-hoc for non-parametric data

  • Mixed-effects models for longitudinal or nested designs

• For correlation analyses:

  • Pearson's correlation for linear relationships between continuous variables

  • Spearman's rank correlation for non-parametric relationships

  • Multiple regression for controlling confounding variables

• Sample size considerations:

  • Power analysis should be performed a priori

  • For immunohistochemical studies, analyze multiple sections per animal

  • For biochemical studies, technical replicates should be averaged before statistical comparison

In studies examining SorCS2 mislocalization in Huntington's disease, quantitative analysis of immunofluorescence intensity has been successfully applied to demonstrate significant differences in staining patterns between control and HD samples .

How can researchers address contradictory findings when different anti-SorCS2 antibodies yield divergent results?

When faced with conflicting results from different SorCS2 antibodies, researchers should implement a systematic troubleshooting approach:

• Epitope mapping comparison:

  • Determine the exact epitopes recognized by each antibody

  • Consider potential masking by post-translational modifications

  • Assess potential for differential detection of SorCS2 isoforms

• Validation in knockout/knockdown systems:

  • Test all antibodies in SorCS2-deficient tissues/cells

  • Quantify non-specific background for each antibody

• Multi-method confirmation:

  • Compare antibody-based methods (WB, IHC, ICC) with non-antibody methods (mRNA analysis, mass spectrometry)

  • Use tagged recombinant SorCS2 expression as positive control

• Standardized comparative testing:

  • Test all antibodies simultaneously under identical conditions

  • Create a detailed documentation of antibody performance characteristics

• Data integration approach:

  • Create a consensus result based on multiple antibodies

  • Weight findings based on validation quality of each antibody

What methodological approaches would best advance understanding of SorCS2's role in neurodegenerative diseases?

Future research on SorCS2 in neurodegenerative contexts would benefit from several methodological innovations:

• Conditional and cell-type specific knockout models:

  • Cre-lox systems targeting SorCS2 in specific neuronal populations

  • Inducible systems to control timing of SorCS2 deletion

  • This would allow dissection of SorCS2 function in specific circuits

• Advanced imaging techniques:

  • Super-resolution microscopy to visualize SorCS2 nanoscale organization

  • Live-cell trafficking studies with pH-sensitive fluorescent tags

  • Expansion microscopy for enhanced subcellular resolution

• Proteomic approaches:

  • Proximity labeling (BioID, APEX) to identify the SorCS2 interactome

  • Quantitative phosphoproteomics to map SorCS2 signaling pathways

  • Crosslinking mass spectrometry to define binding interfaces

• Therapeutic targeting strategies:

  • Development of function-blocking or function-enhancing antibodies

  • Small molecule screening for SorCS2 modulators

  • AAV-mediated gene therapy approaches

These methodological advances would build upon existing findings linking SorCS2 to NR2A trafficking in Huntington's disease and potentially expand understanding of its role in other neurodegenerative conditions.

How can researchers best approach studying the functional interactions between SorCS2 and NMDA receptors in different neuronal populations?

Investigating SorCS2-NMDA receptor functional interactions requires sophisticated approaches that integrate molecular and physiological techniques:

• Electrophysiological assessment:

  • Whole-cell patch-clamp recording of NMDA currents in SorCS2-manipulated neurons

  • Field potential recordings to assess population-level effects

  • Optogenetic stimulation combined with electrophysiology

• Molecular interaction mapping:

  • Domain mapping through deletion constructs to identify critical binding regions

  • Single-molecule imaging to visualize SorCS2-NMDAR complex formation

  • FRET/FLIM analysis to measure protein proximity in living neurons

• Trafficking analysis:

  • Quantum dot tracking of surface NMDARs in SorCS2-deficient neurons

  • Pulse-chase experiments to measure receptor internalization rates

  • Compartment-specific biotinylation to assess receptor distribution

• In vivo functional studies:

  • In vivo calcium imaging during behavior in SorCS2 mutant mice

  • Circuit-specific manipulations using intersectional genetics

  • Correlating behavioral phenotypes with molecular alterations

These approaches would expand upon the findings that SorCS2 deficiency alters NR2A localization on the dendritic plasma membrane and at synapses of medium spiny neurons, contributing to motor deficits in Huntington's disease models .